46 results on '"S. Lobello"'
Search Results
2. THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients
3. THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy
4. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients
5. SAT-262-Long-term liver function outcome and related risk factors in HCV cirrhotic patients treated with direct-acting antiviral therapy: Results from the Navigatore platform in Veneto-Italy
6. EPIDEMIOLOGY
7. P.04.1 BURDEN OF ALCOHOLIC LIVER DISEASE (ALD) ON HOSPITAL ADMISSION IN THE VENETO REGION (NORTHEAST ITALY). A RETROSPECTIVE STUDY BASED ON A LARGE DATABASE
8. Hospitality discharge for alcohol related problems in north east Italy in a sixteen-years period: Influence of new population at risk
9. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study
10. P.09.8 HOSPITALITY DISCHARGE FOR ALCOHOL-RELATED PROBLEMS IN NORTH EAST ITALY IN A SIXTEEN-YEARS PERIOD: INFLUENCE OF NEW POPULATION AT RISK
11. OC.04.6 FROM ALFA-INTERFERON TO DAAS: IMPACT ON HOSPITALIZATION RATE FOR HCV LIVER RELATED DISEASES FROM 2000 TO 2016 IN NORTH EST ITALY
12. Right timing for transient elastography lead the right follow up after HCV treatment
13. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group
14. Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network
15. Chronic Hepatitis D: A Vanishing Disease? An Italian Multicenter Study
16. LP52 : Nonalcoholic fatty liver disease (NAFLD) as potential risk factor of cardiovascular disease and oncological disease in diabetic type 2 patients
17. Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring
18. A cost-consequence analysis of screening and treatment for chronic hepatitis B (CHB) virus infection in resident immigrants of an Italian North-East
19. YIS-4SOCIAL AND HEALTH INTEGRATED APPROACH TO ALCOHOL USE DISORDERS (AUDs) AND ALCOHOL ABUSE/DEPENDENCE: AN ITALIAN EXPERIENCE IN A SPECIALIST SERVICE
20. Hepatitis C virus in healthy immigrants: To screen or not to screen?
21. O4 * FREE ORAL COMMUNICATIONS 4: ALCOHOL INTERVENTIONS IN DIFFERENT SETTINGS
22. 982 BINGE DRINKING, ALCOHOL ABUSE AND DEPENDENCE: SCREENING STUDY IN AN EMERGENCY DEPARTMENT
23. 1280 NAFLD/NASH: MUCH ADO ABOUT NOTHING? A 25 YRS RETROSPECTIVE STUDY IN A COHORT OF DIABETIC PATIENTS
24. 825 SILYBIN CONJUGATED WITH PHOSPHATIDYLCHOLINE AND VITAMIN E IMPROVES LIVER DAMAGE IN PATIENTS WITH NAFLD: THE RESULTS OF A RANDOMIZED MULTICENTRE DOUBLE-BLIND VS PLACEBO TRIAL
25. P1282 A COST–CONSEQUENCE ANALYSIS OF SCREENING AND TREATMENT FOR CHRONIC HEPATITIS B (CHB) VIRUS INFECTION IN RESIDENT IMMIGRANTS OF AN ITALIAN NORTH-EAST REGION
26. Preliminary results of a two-center trial with colchicine for the treatment of chronic hepatitis B
27. High-fat diet and the risk for non-alcoholic fatty liver disease: A population-based study
28. PA.87 ALCOHOL-RELATED PROBLEMS IN HEALTH-WORKERS IN A GENERAL HOSPITAL: A SCREENING STUDY
29. Hepatitis B virus screening in healthy immigrants: A strategy to prevent the spread of infection and to identify and manage chronic hepatitis B (CHB)
30. P.18.1 A PROPER ORGANIZATIONAL MODEL ENCOURAGES HIGH RATE OF INTENTION-TO-TREAT SUSTAINED VIROLOGICAL RESPONSE IN AN INJECTING DRUG USERS HCV+ POPULATION
31. P.03.18 NAFLD/NASH: MUCH ADO ABOUT NOTHING? A 25 YRS RETROSPECTIVE STUDY IN A COHORT OF DIABETIC PATIENTS
32. OC8 SCREENING FOR HBV IN IMMIGRANTS: PILOT PHASE OF EPIDEMIOLOGICAL STUDY IN HEALTY POPULATION
33. F-49 A randomized multicentre double-blind vs placebo trial: Evaluation of effect of silybin conjugated with phosphatidilcholine and vitamin E on liver damage in patients with nonalcoholic fatty liver disease
34. S1839 Effect of Silybin in Patients With Chronic Hepatitis: Preliminary Results of a Multicentre Randomized Controlled Trial vs Placebo
35. 1008 HIGH-FAT DIET AND THE RISK FOR NON-ALCOHOLIC FATTY LIVER DISEASE: A POPULATION BASED-STUDY
36. PO.15 PREVENTION AND EARLY DIAGNOSIS OF COLORECTAL CANCER WITH ENDOSCOPY: WHAT IS USEFUL?
37. Harmful alcohol consumption in health-workers: Results of a screening study
38. Multidisciplinary intervention for management of alcohol-related problems: Results of a thirthy-months experience
39. Gallstones and liver steatosis do not share the same risk factors: Results of the 'Arsita 1' open population survey
40. Binge drinking, alcohol abuse and dependence: Screening study in an emergency department
41. Predictors of response to different protocols of therapy in chronic hepatitis C patients: a large single center experience
42. Long-term follow-up of HBeAg minus chronic hepatitis patients treated with interferon during the peak of anti-HBcIgM
43. Sustained response to 12-month interferon treatment in patients with chronic hepatitis C: A comparison between different IFN doses
44. Daily interferon monotherapy versus daily interferon plus amantadine in the treatment of naive chronic hepatitis C: End of treatment response
45. Daily interferon monotherapy versus daily interferon plus amantadinein the treatment of naive chronic hepatitis C patients: Short-termresponse
46. Household contacts enhance the community risk factors of HCV transmission: A seroepidemiological study in the same open population
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.